BPN14770 is a selective PDE4D inhibitor. PDE4 degrades cAMP, so blocking it sustains elevated cAMP levels that keep PKA active, which phosphorylates CREB, which drives expression of BDNF and other plasticity genes. The subtype selectivity for PDE4D matters practically: non-selective PDE4 inhibitors like rolipram cause significant nausea via PDE4B activity in the brainstem. BPN14770 largely spares PDE4B, making it a more tolerable entry point into the cAMP/CREB plasticity pathway.
The synergy with ACD-856 is the main reason this is interesting. ACD-856 sensitizes TrkB receptors to BDNF, more signal per unit of BDNF. BPN14770 keeps cAMP elevated downstream of the same BDNF-TrkB cascade, extending the duration of the plasticity signal. They work on adjacent nodes of the same pathway without receptor overlap, which is the cleanest kind of stack.
- Human use not well characterized
- animal-to-human extrapolation from rodent studies suggests 10–30mg range, and even sub-selective PDE4 inhibitors can cause nausea dose-dependently
- starting low is non-negotiable.